StreetInsider.com News Articles

Cytokinetics to Announce Third Quarter Results on November 4, 2026

Wed, 21 Oct 2026 16:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.

The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com or directly at the following link: Cytokinetics

Cytokinetics to Announce Third Quarter Results on November 4, 2026

Wed, 21 Oct 2026 16:00:00 -0400

Form 4 CYTOKINETICS INC For: Oct 16 Filed by: Wysenski Nancy

Tue, 20 Oct 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20261020/27210940.html

Form 4 CYTOKINETICS INC For: Oct 16 Filed by: Kaye Edward M. MD

Tue, 20 Oct 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20261020/27210925.html

Form 4 CYTOKINETICS INC For: Oct 16 Filed by: Harrington Robert Arthur

Tue, 20 Oct 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20261020/27210905.html

Form 4 CYTOKINETICS INC For: Oct 16 Filed by: Daly James M

Tue, 20 Oct 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20261020/27210896.html

Form 4 CYTOKINETICS INC For: Oct 16 Filed by: WIERENGA WENDELL

Tue, 20 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261020/27210887.html

Form 4 CYTOKINETICS INC For: Oct 16 Filed by: HENDERSON JOHN T

Tue, 20 Oct 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20261020/27210817.html

Form 144 CYTOKINETICS INC Filed by: Malik Fady Ibraham

Tue, 20 Oct 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20261020/27210787.html

Form 4 CYTOKINETICS INC For: Oct 20 Filed by: Malik Fady Ibraham

Tue, 20 Oct 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20261020/27210736.html

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 19 Oct 2026 16:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2026 it granted stock options to purchase an aggregate of 60,465 shares of common stock and 40,084 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 29 employees, whose employment commenced in September and October 2026 as a material inducement to their employment.

The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 19 Oct 2026 16:00:00 -0400

The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of

Health Canada approves Cytokinetics' aficamten for heart condition

Mon, 19 Oct 2026 07:31:59 -0400

Cytokinetics, Incorporated (Nasdaq: CYTK) announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults with New York Heart Association class II-III disease.

The Canadian authorization is the fifth regulatory approval for MYQORZO in less than a year, according to the company. The drug was previously approved by the U.S. Food and Drug Administration in December 2025, followed by China's National Medical Products Administration, the European Commission, and the UK's Medicines and Healthcare products Regulatory Agency earlier in 2026.

MYQORZO is a once-daily oral cardiac myosin inhibitor that reduces

Health Canada approves Cytokinetics' aficamten for heart condition

Mon, 19 Oct 2026 07:31:59 -0400

MYQORZO is a once-daily oral cardiac myosin inhibitor that reduces

Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Mon, 19 Oct 2026 07:30:00 -0400

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) class II-III in adult patients. MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.

“This company milestone marks the fifth regulatory approval for MYQORZO in less than a year

Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Mon, 19 Oct 2026 07:30:00 -0400

“This company milestone marks the fifth regulatory approval for MYQORZO in less than a year

William Blair Starts Cytokinetics (CYTK) at Outperform

Thu, 15 Oct 2026 16:50:50 -0400

William Blair analyst Alethia Young initiates coverage on Cytokinetics (NASDAQ: CYTK) with a Outperform rating.

The analyst comments "We are initiating coverage of Cytokinetics with an Outperform rating, and our DCF-based valuation is $101/share. Cytokinetics is a commercial-stage specialty cardiology company built around muscle biology and its first approved product, MYQORZO. Our CYTK call: We have conviction in a strong MYQORZO launch through 2027. Around mid-2027, we model nHCM approval, assuming priority review, adding ~100K addressable patients. We estimate 2032 sales of ~$3.74B. Key risks are MYQORZO commercial launch, regulatory, and clinical execution."

For an analyst ratings summary and ratings history on

William Blair Starts Cytokinetics (CYTK) at Outperform

Thu, 15 Oct 2026 16:50:50 -0400

William Blair analyst Alethia Young initiates coverage on Cytokinetics (NASDAQ: CYTK) with a Outperform rating.

For an analyst ratings summary and ratings history on

Cytokinetics (CYTK) PT Lowered to $104 at UBS

Wed, 14 Oct 2026 06:51:52 -0400

UBS analyst Ashwani Verma lowered the price target on Cytokinetics (NASDAQ: CYTK) to $104.00 (from $115.00) while maintaining a Buy rating.

The analyst comments "We see CYTK as an attractive launch name (oHCM) that has the added benefit of diversification (nHCM) and potential removal of competitive overhang (EWTX). Similar to a number of other commercial biotech names (NBIX, AXSM, JAZZ, UTHR, INSM), CYTK has also underperformed recently as XBI pulled back. However, if interest-rate hike cycle is likely to drive further "risk-off" environment, we believe names like CYTK can outperform from current levels. In our view, Myqorzo will see continued sales

Cytokinetics (CYTK) PT Lowered to $104 at UBS

Wed, 14 Oct 2026 06:51:52 -0400

UBS analyst Ashwani Verma lowered the price target on Cytokinetics (NASDAQ: CYTK) to $104.00 (from $115.00) while maintaining a Buy rating.

Form 4 CYTOKINETICS INC For: Oct 12 Filed by: Blum Robert I

Tue, 13 Oct 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20261013/27181002.html

Form 144 CYTOKINETICS INC Filed by: Blum Robert I

Tue, 13 Oct 2026 08:20:00 -0400

si-local-file:///var/storage/secattach/20261013/27177680.html

Cytokinetics shares new aficamten data for non-obstructive HCM

Mon, 12 Oct 2026 16:03:15 -0400

Cytokinetics, Incorporated (Nasdaq: CYTK) presented additional data from its ACACIA-HCM clinical trial at the Heart Failure Society of America Annual Scientific Meeting 2026 in Phoenix, Arizona, according to a company press release.

The data covered three areas: comprehensive exercise performance, a global efficacy responder analysis, and dose titration and safety. In the exercise performance analysis, treatment with aficamten significantly improved scores on the Boston Exercise Aggregate Physiologic Response Score at 36 weeks compared to placebo (p<0.001), with gains across all five measured domains. Score improvements correlated with health status measures and the cardiac biomarker NT-proBNP.

In the responder analysis, 53% of patients

Cytokinetics shares new aficamten data for non-obstructive HCM

Mon, 12 Oct 2026 16:03:15 -0400

In the responder analysis, 53% of patients

Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026

Mon, 12 Oct 2026 16:00:00 -0400

Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 in Phoenix, AZ.

“These additional analyses from ACACIA-HCM add to the body of evidence supporting the overall benefit-risk profile of aficamten in patients with nHCM,” said